Chengdu Olymvax Biopharmaceuticals Inc. Class ASSE: 688319

"Chengdu Olymvax Biopharmaceuticals Inc."Voluntary Disclosure Announcement on the Unblinding Results of the Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine (E. coli)

Jul 11, 2026 · Issued by Chengdu Olymvax Biopharmaceuticals Inc. Class A via Shanghai Stock Exchange

Voluntary Disclosure Announcement on the Unblinding Results of the Phase III Clinical Trial of Recombinant Staphylococcus Aureus Vaccine (E. coli)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Chengdu Olymvax Biopharmaceuticals Inc. Class A

"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Voluntary Disclosure of Winning the Second Prize of the 2025 National Technological Invention AwardJul 9
"Chengdu Olymvax Biopharmaceuticals Inc."Announcement on Receiving Government SubsidiesJul 1
Announcement on the Implementation of Repurchase and Cancellation of the Class A Restricted Shares Initially Granted under the 2023 Restricted Stock Incentive PlanJun 23
Announcement on Tax Payment RemediationJun 22

All Chengdu Olymvax Biopharmaceuticals Inc. Class A news releases